Lawsuit Alleges TPG Sacrificed Patient Safety for Profit in Exactech Scandal

PORT WASHINGTON, N.Y. – February 10, 2026 – A bombshell lawsuit filed in the Delaware Court of Chancery accuses private equity titan TPG Inc. of orchestrating a scheme to conceal dangerous defects in orthopedic implants, delay life-saving recalls, and ultimately force medical device maker Exactech into bankruptcy to shield itself from billions in liability. The suit, brought forth by the Exactech Litigation Trust, has gained the vocal support of Parker Waichman LLP, a national law firm representing numerous patients who claim they were severely harmed by the company's faulty devices.

The legal action, filed on February 5, alleges that TPG, after acquiring Exactech in a $737 million deal in 2018, prioritized its investment returns over the well-being of patients. It claims the private equity firm exerted majority control over Exactech's board and management, making critical decisions that allegedly magnified the harm caused by prematurely failing knee, hip, and ankle implants.

The Human Cost of an Alleged Cover-Up

For thousands of individuals, the promise of restored mobility through joint replacement surgery has turned into a nightmare of chronic pain, instability, and debilitating revision procedures. The core of the problem stems from recalls initiated by Exactech between 2021 and 2022, affecting hundreds of thousands of implants manufactured since 2004. The company admitted that defective vacuum-sealed packaging allowed oxygen to penetrate and degrade the polyethylene inserts in the devices.

This oxidation process caused the plastic components to wear out far earlier than expected, leading to catastrophic device failure. Patients experienced severe pain, bone loss, and component fractures, often necessitating complex and painful revision surgeries to remove and replace the failed implants. Some have had to endure multiple such operations.

Now, these injured patients find themselves in a precarious position. When Exactech filed for Chapter 11 bankruptcy in October 2024, citing the mounting pressure of over 2,600 personal injury claims, it automatically halted all individual lawsuits. The victims were reclassified as unsecured creditors, facing an uncertain path to compensation for their immense medical bills, lost wages, and profound suffering. The lawsuit filed by the Trust represents their primary hope for a meaningful recovery, seeking to claw back value for their benefit.

From Acquisition to Bankruptcy: A Timeline of Accusations

The Trustee's complaint paints a damning picture of corporate decision-making following TPG's 2018 acquisition. It alleges that TPG installed its own personnel in key leadership and board positions, effectively controlling Exactech's operational, regulatory, and litigation strategies. According to the lawsuit, this control was used to suppress information about the known defects and delay recalls, maximizing profits while the devices continued to be implanted in unsuspecting patients.

This strategy allegedly culminated in the Chapter 11 filing, which the suit frames as a calculated maneuver to cap TPG's exposure to the spiraling product liability crisis. An earlier proposal within the bankruptcy proceedings that would have granted TPG broad legal immunity in exchange for a mere $10 million contribution was fiercely opposed by creditors and ultimately abandoned, signaling the resolve of victims and their advocates to pursue full accountability.

"The Trustee's complaint echoes what injured patients have long alleged — that corporate decision-making delayed recalls and magnified the harm to the patients that used their devices," said Jason Goldstein, Senior Litigation Counsel at Parker Waichman LLP, in a statement. "Unsecured personal-injury claimants should not be left holding the bag while those who allegedly controlled the company extracted value and avoided accountability and liability."

A Legal Precedent in the Making

At the heart of the Delaware lawsuit is a formidable legal strategy seeking to “pierce the corporate veil.” The complaint argues that TPG operated as the "alter ego" of Exactech, rendering the distinction between the two entities a mere façade. By alleging that TPG micromanaged its subsidiary to such an extent, the Trust aims to hold the parent investment firm directly liable for the debts and obligations of the bankrupt device maker.

Successfully proving an alter ego claim is notoriously difficult, especially in Delaware's business-friendly courts, which set a high bar for disregarding corporate separateness. However, the case lands amid growing scrutiny of the role private equity plays in critical sectors like healthcare. A victory for the Trust could set a monumental precedent, signaling to investment firms that they may be held directly responsible for the actions of portfolio companies, particularly when public health is at stake.

The lawsuit's success could reshape due diligence in mergers and acquisitions and force private equity owners to weigh patient safety more heavily against financial returns. For the thousands of unsecured creditors, it represents the most significant path toward a recovery that acknowledges the full scope of their devastating injuries. Parker Waichman LLP has affirmed its commitment to supporting these efforts, emphasizing that a full adjudication of the claims is essential for achieving a just outcome for those harmed by the recalled Exactech medical devices.